跳至主要内容
临床试验/KCT0004609
KCT0004609尚未招募未知

PET imaging of patients with elevated PSA using [F-18]Florastamin: Phase I clinical trial

FutureChem0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
20(Year) 至 o Limit(—)
性别
Male

入选标准

  • Prostate cancer patient group
  • 1. Prostate cancer patient diagnosed histologically
  • - Patient diagnosed with prostate cancer by planning surgery and performing biopsy
  • - Patients with elevated PSA after prostatectomy or radiation therapy
  • - Patients found with clinical progression of prostate cancer
  • 2. Subjects who have been fully informed of the purpose and contents of the trial and characteristics of the investigational product before enrolling in the clinical trial by subinvestigators and signed the consent form by themselves, their guardian or a legal representative.
  • 3. Male patient aged 19 or older
  • 4. ECOG _ Performance scale =2
  • 5. Expect at least 12 months of survival
  • 6. Those who meet the following conditions in blood tests, renal and liver function tests
  • - Platelet count (PLT)> 50,000/µL
  • - BUN and serum creatinine <1.5 x upper limit of normal (ULN)
  • - AST and ALT <2.5 x upper limit of normal (ULN)
  • - Left ventricle ejection fraction > 60% if there is a history of heart disease

排除标准

  • 1. Those who were judged as difficult to conduct the clinical trial due to serious medical conditions by the investigator
  • 2. Those who were judged to have a mental illness that makes it difficult to obtain positron emission tomography (PET) by the investigator
  • 3. Participant in another clinical trial that may affect [F-18]Florastamin PET image acquisition from enrolling in the clinical trial to the end of the clinical trial or may affect the safety assessment following intravenous injection of [F-18]Florastamin (e.g., a subject from a cohort clinical trial that is conducted with only a follow-up observation without receiving the investigational product from enrollment until the end of the clinical trial can participate.)
  • 4. Those who were judged as inappropriate to participate in the clinical trial by the investigator
  • 5. Vulnerable subjects (investigator self or one’s family who participated in the trial, investigator or students of investigator who participated in the study, or families of the subjects)

研究者

发起方
FutureChem

相似试验

Phase 1 clinical trial for PET image evaluation of... | 临床试验